Multi-omics analysis reveals therapeutic effects of Bacillus subtilis-fermented Astragalus membranaceus in hyperuricemia via modulation of gut microbiota

• Published in: Food chemistry 2023-01, Vol.399, p.133993-133993, Article 133993
• Main Authors: Wang, Ruoyu, Lin, Feng, Ye, Chen, Aihemaitijiang, Sumiya, Halimulati, Mairepaiti, Huang, Xiaojie, Jiang, Zeyu, Li, Lutong, Zhang, Zhaofeng
• Format: Article
• Language: English
• Subjects: Astragalus membranaceus; Bacillus subtilis; Fermentation; Gut microbiota; Hyperuricemia
• ISSN: 0308-8146; 1873-7072
• DOI: 10.1016/j.foodchem.2022.133993

[Display omitted] •Hyperuricemia has become a public health problem that needs to be solved urgently.•Astragalus may have great potential in reducing uric acid.•Bacillus subtilis-fermenting Astragalus can ameliorate hyperuricemia in mice via improving metabolic disorder ofintestinalflora and ameliorating inflammation using multi-omics approaches. At present, uncovering how to preventandcontrol hyperuricemia has become an important public health issue. Fermented traditionalChinesemedicine has exhibited promising applications in the clinical management of hyperuricemia. In this study, we generated a hyperuricemic mouse model to explore the potent therapeutic ability of Bacillus subtilis-fermented Astragalus membranaceus (BFA) on this condition by multi-omics analysis. We found that the serum uric acid level was decreased in hyperuricemic mice after BFA treatment. BFA effectively attenuated renal inflammation and regulated the expression of urate transporters. Additionally, we found that BFA could increase the abundances of butyrate-producing bacteria, including Butyricimonas synergistica, Odoribacter splanchnicus, and Collinsella tanakaei, and probiotics, including Lactobacillus intestinalis and Bacillus mycoides, in hyperuricemic mice. Therefore, we believe that BFA has the potential to become a novel safe and valid functional food for addressing hyperuricemia.